ZyVersa Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $26 | $0 | $0 | $15 |
Gross Profit | 13 | -2 | -10 | |
EBITDA | -1,286 | -2,267 | -2,751 | -2,816 |
EBIT | -1,271 | -2,269 | -2,753 | -2,826 |
Net Income | -1,421 | -2,401,256 | -2,763 | -2,826 |
Net Change In Cash | 26 | 0 | 0 | 15 |
Free Cash Flow | -4,475,406 | -3,078,600 | -1,914 | -3,776 |
Cash | 1,530 | 122 | 119 | 2,033 |
Basic Shares | 11,100 | 9,883 | 834 | 623 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -10 | -10 | -10 | |
EBITDA | -9,136,834 | -107,743 | -11,671 | -7,252 |
EBIT | -9,150,324 | -107,753 | -11,682 | -7,262 |
Net Income | -9,413,435 | -98,297 | -759,097 | -8,905 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -7,559,697 | -8,720 | -1,494 | -5,076 |
Cash | 1,530 | 3,137 | 5,902 | 328 |
Basic Shares | 11,100 | 97 | 25 | 46 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-03-31 | -$1.31 |
2024-09-30 | -$2.43 |
2024-06-30 | -$3.31 |
2024-03-31 | -$4.53 |
